Q-omics provides the consensus-scored IFT172 profile across patient tissues and cancer cell-line models. IFT172 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, IFT172 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, IFT172 RNA expression shows 20,835 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, KICH, and KIRP as cancer lineages where IFT172 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFT172 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFT172 survival associations across molecular data types. IFT172 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFT172 RNA expression–survival associations across cancer types. High IFT172 expression shows unfavorable associations in LIHC, KICH, LGG and BLCA, but favorable associations in HNSC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for IFT172 RNA expression.
This table summarizes IFT172 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IFT172. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFT172 shows lower tumor expression in KICH, THCA and BLCA and higher tumor expression in LIHC, COAD and CHOL. The KICH box plot shows higher IFT172 RNA expression in normal versus tumor tissue (log2 FC = −1.705, t-test p < 0.001).
This table shows molecular features associated with IFT172 in patient tissues and cancer cell lines. In patient samples, IFT172 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, IFT172 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
